EUVIMEDEUVIMED entdecken
Crossref

New follow-up methodologies for acute leukemias in allogenic hematopoietic stem cell transplantation

Serra, C., Gabriela Martins, Fernandes, B., Inês Godinho, Palmeira, C., Sousa, M.E.

Proceedings of Research and Practice in Allied and Environmental Health · 08.09.2025

DOI: 10.26537/prpaeh.v2i4.6464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of Research and Practice in Allied and Environmental Health, erschienen am 08.09.2025. Verfasst von Serra und 9 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is considered a potential therapy for long-term survival, used as post-remission therapy in leukemias whose response to earlier treatments was not effective. Relapse and associated disease progression are some of the main complications after the transplantation period that may lead to uncertain clinical endings. Transplantation monitoring markers must be effective in the follow-up disease [1-5].

Aim

This study aimed to evaluate the presence of mixed chimerism (MC) in peripheral blood along the follow-up of patients after Allo-HSCT to optimize the predictive value of recurrence of the underlying disease.

Methods

Peripheral blood samples from 143 individuals with Acute Myeloblastic Leukemia (AML) and 80 individuals with B/T Cell Acute Lymphoblastic Leukemia (LLB/T) between January 2013 and December 2019. Chimerism conditions were performed at the first moment of evidence of MC and one year after transplantation, using a PCR multiplex (Mentype® Chimera®) from Biotype.

Results

The mean age of patients undergoing transplantation was 43.8 and 31 years and the mean survival was 11,1 and 12 months for AML and LLB/T patients, respectively. After 1 year of HSCT, 30% and 31,7% of LLB/T and AML patients showed complete chimerism (CC), opposed 70% and 68,3% exhibit MC. However, 68% and 72% of that denote a progressive MC. On LLB/T and AML patients, 50% and 60% keeped MC; 39% and 33% evolved from MC to CC; 11% and 5% regressed from CC to MC, respectively.

Conclusions

The evaluation of chimerism over one year of Allo-HSCT in both leukemias, concluded that although the percentage of CC was lower than the MC, the percentage of progressive chimerism was significantly more evident than decreasing chimerism, which may indicate a decrease probably of recurrence and a better prognosis. Most patients maintained stable MC, supporting the idea of balance between donor and recipient cells, or evolved from MC to CC, which shows a positive evolution in transplant engraftment [6-12].

Schlagwörter

allogeneic hematopoietic stem cell transplantationacute leukemiamixed chimerismcomplete chimerismrecurrenceacute myeloid leukemiapost-transplant monitoringchimerism monitoringprognostic factors

Zitieren

APA

Serra, C., Martins, G., Fernandes, B., Godinho, I., Palmeira, C., Sousa, & M.E. (2025). New follow-up methodologies for acute leukemias in allogenic hematopoietic stem cell transplantation. Proceedings of Research and Practice in Allied and Environmental Health. https://doi.org/10.26537/prpaeh.v2i4.6464

Vancouver

Serra, C., Martins G, Fernandes, B., Godinho I, et al. New follow-up methodologies for acute leukemias in allogenic hematopoietic stem cell transplantation. Proceedings of Research and Practice in Allied and Environmental Health. 2025. doi:10.26537/prpaeh.v2i4.6464

BibTeX
@article{Serra2025,
  author = {Serra and C. and Martins, Gabriela and Fernandes and B. and Godinho, Inês and Palmeira and C. and Sousa and M.E.},
  title = {New follow-up methodologies for acute leukemias in allogenic hematopoietic stem cell transplantation},
  journal = {Proceedings of Research and Practice in Allied and Environmental Health},
  year = {2025},
  doi = {10.26537/prpaeh.v2i4.6464}
}
Kostenlos starten →